Multiplicity in oncology randomised controlled trials: a threat to medical evidence?

Vinay Prasad; Christopher M. Booth

doi:10.1016/S1470-2045(19)30744-2

Multiplicity in oncology randomised controlled trials: a threat to medical evidence?

Vinay Prasad, Christopher M. Booth

Knight Cancer Institute

Research output: Contribution to journal › Comment/debate › peer-review

9 Scopus citations

Original language	English (US)
Pages (from-to)	1638-1640
Number of pages	3
Journal	The Lancet Oncology
Volume	20
Issue number	12
DOIs	https://doi.org/10.1016/S1470-2045(19)30744-2
State	Published - Dec 2019

ASJC Scopus subject areas

Oncology

Access to Document

10.1016/S1470-2045(19)30744-2

Cite this

@article{91a8c51c8d224a238a103c6a2c72a455,

title = "Multiplicity in oncology randomised controlled trials: a threat to medical evidence?",

author = "Vinay Prasad and Booth, {Christopher M.}",

note = "Funding Information: VP is supported by the Arnold Foundation. CMB is supported as the Canada Research Chair in Population Cancer Care. We gratefully acknowledge Elizabeth Eisenhauer and Ian Tannock for comments on an earlier draft of this manuscript. VP reports receiving royalties from his book Ending Medical Reversal and an advance for the forthcoming book Malignant: How Bad Policy and Bad Evidence Work Against People With Cancer. VP's work is funded by the Laura and John Arnold Foundation and VP has received honoraria for Grand Rounds/lectures from several universities, medical centres, and professional societies and payments for contributions to Medscape. VP also hosts the podcast Plenary Session, which has Patreon backers. CMB declares no competing interests.",

year = "2019",

month = dec,

doi = "10.1016/S1470-2045(19)30744-2",

language = "English (US)",

volume = "20",

pages = "1638--1640",

journal = "The Lancet Oncology",

issn = "1470-2045",

publisher = "Lancet Publishing Group",

number = "12",

}

TY - JOUR

T1 - Multiplicity in oncology randomised controlled trials

T2 - a threat to medical evidence?

AU - Prasad, Vinay

AU - Booth, Christopher M.

N1 - Funding Information: VP is supported by the Arnold Foundation. CMB is supported as the Canada Research Chair in Population Cancer Care. We gratefully acknowledge Elizabeth Eisenhauer and Ian Tannock for comments on an earlier draft of this manuscript. VP reports receiving royalties from his book Ending Medical Reversal and an advance for the forthcoming book Malignant: How Bad Policy and Bad Evidence Work Against People With Cancer. VP's work is funded by the Laura and John Arnold Foundation and VP has received honoraria for Grand Rounds/lectures from several universities, medical centres, and professional societies and payments for contributions to Medscape. VP also hosts the podcast Plenary Session, which has Patreon backers. CMB declares no competing interests.

PY - 2019/12

Y1 - 2019/12

UR - http://www.scopus.com/inward/record.url?scp=85075648044&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85075648044&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(19)30744-2

DO - 10.1016/S1470-2045(19)30744-2

M3 - Comment/debate

C2 - 31797779

AN - SCOPUS:85075648044

SN - 1470-2045

VL - 20

SP - 1638

EP - 1640

JO - The Lancet Oncology

JF - The Lancet Oncology

IS - 12

ER -

Multiplicity in oncology randomised controlled trials: a threat to medical evidence?

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this